Londero Francesco, Grossi William, Morelli Angelo, Parise Orlando, Masullo Gianluca, Tetta Cecilia, Livi Ugolino, Maessen Jos G, Gelsomino Sandro
Department of Cardiothoracic Surgery, S. Maria della Misericordia University Hospital, Udine, Italy.
Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands.
Future Sci OA. 2020 Apr 15;6(5):FSO471. doi: 10.2144/fsoa-2019-0120.
It is not clear as to which is the best treatment among surgery and stereotactic radiotherapy (SBRT) for lung oligometastases. A systematic review of literature with selection criteria was conducted on articles on the treatment of pulmonary metastases with surgery or SBRT. Only original articles with a population of patients of more than 50 were selected. After final selection, 61 articles on surgical treatment and 18 on SBRT were included. No difference was encountered in short-term survival between pulmonary metastasectomy and SBRT. In the long-term surgery seems to guarantee better survival rates. Mortality and morbidity after treatment are 0-4.7% and 0-23% for surgery, and 0-2% and 4-31% for SBRT. Surgical metastasectomy remains the treatment of choice for pulmonary oligometastases.
对于肺部寡转移瘤，手术和立体定向放射治疗（SBRT）哪种是最佳治疗方法尚不清楚。我们根据选择标准对关于手术或SBRT治疗肺转移瘤的文章进行了系统的文献综述。仅选择患者人数超过50的原始文章。最终筛选后，纳入了61篇关于手术治疗的文章和18篇关于SBRT的文章。肺转移瘤切除术和SBRT在短期生存率方面没有差异。从长期来看，手术似乎能保证更好的生存率。手术治疗后的死亡率和发病率分别为0 - 4.7%和0 - 23%，SBRT的死亡率和发病率分别为0 - 2%和4 - 31%。手术切除转移瘤仍是肺部寡转移瘤的首选治疗方法。
